Borderline ER-Positive Primary Breast Cancer Gains No Significant Survival Benefit From Endocrine Therapy: A Systematic Review and Meta-Analysis

Heldring, 2007, Estrogen receptors: how do they signal and what are their targets, Physiol Rev, 87, 905, 10.1152/physrev.00026.2006

Freedman, 2015, Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline, Curr Oncol, 22, S95, 10.3747/co.22.2326

Bliss, 2012, Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study, J Clin Oncol, 30, 709, 10.1200/JCO.2010.33.7899

Burstein, 2014, Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update, J Clin Oncol, 32, 2255, 10.1200/JCO.2013.54.2258

Andre, 2008, Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis, J Clin Oncol, 26, 2636, 10.1200/JCO.2007.14.9146

Hammond, 2010, American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer, J Oncol Pract, 6, 195, 10.1200/JOP.777003

Viale, 2007, Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98, J Clin Oncol, 25, 3846, 10.1200/JCO.2007.11.9453

Raghav, 2012, Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers, Cancer, 118, 1498, 10.1002/cncr.26431

Yi, 2014, Which threshold for ER positivity? A retrospective study based on 9639 patients, Ann Oncol, 25, 1004, 10.1093/annonc/mdu053

Balduzzi, 2014, Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression, Clin Breast Cancer, 14, 258, 10.1016/j.clbc.2013.10.019

Honma, 2014, Proportion of estrogen or progesterone receptor expressing cells in breast cancers and response to endocrine therapy, Breast, 23, 754, 10.1016/j.breast.2014.08.003

Harvey, 1999, Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer, J Clin Oncol, 17, 1474, 10.1200/JCO.1999.17.5.1474

Dowsett, 2008, Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial, J Clin Oncol, 26, 1059, 10.1200/JCO.2007.12.9437

Regan, 2006, Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays, J Natl Cancer Inst, 98, 1571, 10.1093/jnci/djj415

Elledge, 2000, Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study, Int J Cancer, 89, 111, 10.1002/(SICI)1097-0215(20000320)89:2<111::AID-IJC2>3.0.CO;2-W

Viale, 2008, Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors–International Breast Cancer Study Group, J Clin Oncol, 26, 1404, 10.1200/JCO.2007.10.6393

Collins, 2005, Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases, Am J Clin Pathol, 123, 16, 10.1309/HCF035N9WK40ETJ0

Moher, 2010, Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement, Int J Surg, 8, 336, 10.1016/j.ijsu.2010.02.007

Iwamoto, 2012, Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry, J Clin Oncol, 30, 729, 10.1200/JCO.2011.36.2574

Brdar, 1988, Estrogen and progesterone receptors as prognostic factors in breast cancer, Tumori, 74, 45, 10.1177/030089168807400108

Manni, 1980, Estrogen and progesterone receptors in the prediction of response of breast cancer to endocrine therapy, Cancer, 46, 2838, 10.1002/1097-0142(19801215)46:12+<2838::AID-CNCR2820461421>3.0.CO;2-A

Osborne, 1980, The value of estrogen and progesterone receptors in the treatment of breast cancer, Cancer, 46, 2884, 10.1002/1097-0142(19801215)46:12+<2884::AID-CNCR2820461429>3.0.CO;2-U

Carroll, 2006, Genome-wide analysis of estrogen receptor binding sites, Nat Genet, 38, 1289, 10.1038/ng1901

Hah, 2011, A rapid, extensive, and transient transcriptional response to estrogen signaling in breast cancer cells, Cell, 145, 622, 10.1016/j.cell.2011.03.042

Albert, 2011, Patients with only 1 positive hormone receptor have increased locoregional recurrence compared with patients with estrogen receptor-positive progesterone receptor-positive disease in very early stage breast cancer, Cancer, 117, 1595, 10.1002/cncr.25694

Chia, 2012, A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen, Clin Cancer Res, 18, 4465, 10.1158/1078-0432.CCR-12-0286

Riseberg, 2015, Treating elderly patients with hormone receptor-positive advanced breast cancer, Clin Med Insights Oncol, 9, 65, 10.4137/CMO.S26067